Johnson & Johnson (JNJ) Declares $0.84 Quarterly Dividend; 2.4% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Johnson & Johnson (JNJ) PT Raised to $145 at Morgan Stanley
October 18, 2017 7:49 AM EDTMorgan Stanley raised its price target on Johnson & Johnson (NYSE: JNJ) to $145.00 (from $140.00) while maintaining a Overweight rating.
... MoreJohnson & Johnson (JNJ) PT Raised to $161 at Jefferies
October 18, 2017 7:30 AM EDTJefferies raised its price target on Johnson & Johnson (NYSE: JNJ) to $161.00 (from $160.00) while maintaining a Buy rating following beat and raise results.
Analyst Jeffrey Holford notes their revenue and adjusted EPS estimates remain well above consensus.
"The Pharma division remains under-modeled by... More
Johnson & Johnson (JNJ) PT Raised to $165 at Leerink Partners
October 18, 2017 7:03 AM EDTLeerink Partners raised its price target on Johnson & Johnson (NYSE: JNJ) to $165.00 (from $150.00) while maintaining a Outperform rating.
Analyst Danielle Antalffy said outperformance highlights momentum. 217/2018 outlook moves higher.
... MoreJohnson & Johnson (JNJ) PT Raised to $142 at Stifel on 3Q Earnings Report; 'Pharma Carries the Day, Hurricane Headwinds Encouragingly Modest
October 17, 2017 5:16 PM EDTStifel raised its price target on Johnson & Johnson (NYSE: JNJ) to $142.00 (from $140.00) while maintaining a Hold rating, following the company's third quarter earnings report.
Analyst Rick Wise notes a positive outlook, as the company reported third quarter earnings per share and revenue results above... More
Johnson & Johnson (JNJ) Wins Reversal of First St. Louis Talc-Cancer Verdict - Bloomberg
October 17, 2017 12:00 PM EDTJohnson & Johnson (NYSE: JNJ) Wins Reversal of First St. Louis Talc-Cancer Verdict - Bloomberg
... MoreDow pierces 23,000 but ends below milestone
October 17, 2017 7:41 AM EDTBy Caroline Valetkevitch
NEW YORK (Reuters) - The Dow Jones Industrial Average briefly broke above the 23,000-point mark for the first time on Tuesday, driven by strong earnings from UnitedHealth and Johnson & Johnson, but finished the session just below that milestone.
The blue-chip index, which surpassed similar 1,000-point marks three times previously this year, has been steadily inching higher and is up 2.6 percent so far this month, putting it on track for a seventh straight monthly advance.
The Dow may in the near term have a difficult time sustaining a move above 23,000, said Robert Pavlik, chief... More
Johnson & Johnson (JNJ) Tops Q3 EPS by 10c; Raises Outlook
October 17, 2017 6:42 AM EDTJohnson & Johnson (NYSE: JNJ) reported Q3 EPS of $1.90, $0.10 better than the analyst estimate of $1.80. Revenue for the quarter came in at $19.7 billion versus the consensus estimate of $19.28 billion.
GUIDANCE:
Johnson & Johnson raised its FY outlook. The company sees FY2017 EPS of... More
